Analyst Update: SanDisk Corporation, Esperion Therapeutics Inc, and Jazz Pharmaceuticals plc - Ordinary Shares

Analysts adjusted their ratings on SanDisk Corporation (SNDK), Esperion Therapeutics Inc (ESPR), and Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)

by Griffin Kruse

Published on Mar 27, 2015 at 11:33 AM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on data solutions specialist SanDisk Corporation (NASDAQ:SNDK), as well as biopharmaceutical firms Esperion Therapeutics Inc (NASDAQ:ESPR) and Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ:JAZZ). Here's a quick look at today's brokerage notes on SNDK, ESPR, and JAZZ.

  • The fallout from yesterday's decreased revenue guidance is still affecting SNDK, as no fewer than eight brokerage firms reduced their opinion on the equity. Drilling down, the most dramatic cuts came from Wedbush and BMO -- to $56 and $61, respectively. After suffering its worst drop in five years yesterday, the shares of SanDisk Corporation are down 1.8% to hit $65.03 -- and earlier touched an annual low of $64.45 -- bringing the equity's year-to-date deficit to 33.7%. The brokerage bunch is still mostly bullish on SNDK, though, as 71% of covering analysts rate the stock a "buy" or better, with no "sell" or worse recommendations to be found. This leaves the door wide open for another round of negative analyst notes to pressure the shares even lower.

  • Citigroup started coverage on ESPR with a "buy" rating and a lofty $130 price target -- in uncharted territory -- sending the shares up 5.2% to hit $93.12. Digging deeper, the brokerage firm said ESPR's cholesterol-lowering drug is "an attractive asset for pharma to in-license or acquire." While Esperion Therapeutics Inc has dropped 21.7% from its March 19 record high of $118.95, the shares remain nearly 500% higher year-over-year. As such, the brokerage bunch is unanimously optimistic on the security, as all three covering analysts rate the stock a "buy" or better. Additionally, ESPR's average 12-month price target of $107.17 represents a 15% premium to current trading levels.

  • Citigroup also initiated JAZZ with a "buy" rating alongside a $195 price target -- in unexplored terrain. On the charts, Jazz Pharmaceuticals plc is up 2.1% at $177.09, bringing its year-to-date gain to 8.2%. In fact, JAZZ just tagged an all-time peak of $190.17 on March 19. Accordingly, sentiment in the options pits has been bullish, as JAZZ's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 2.70 stands in the 99th percentile of its annual range.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


With This Lithium Stock, It Will Be Better to Be Too Early Than Too Late
Click to continue to advertiser's site.
TSCO Wheels Higher on Upbeat Forecast
TSCO has nearly doubled off its March lows
Boeing Stock Gets Lift on Layoff Buzz
Boeing is expected to announce over 2,500 voluntary layoffs by Friday
With This Lithium Stock, It Will Be Better to Be Too Early Than Too Late
Click to continue to advertiser's site.